Patients with Early-Stage and Estrogen Receptor-Negative Breast Cancers: Young Age Does Link to Poor Outcomes

Yanyan Xie,Lv Qing,Yao Wang,Yuting Zhou,Juanjuan Qiu,Qianru Yang,Zhenggui Du
DOI: https://doi.org/10.4236/ijcm.2019.1012055
2019-01-01
International Journal of Clinical Medicine
Abstract:Purpose: This study aimed to evaluate whether young adult breast cancer patients have poor outcomes independent of established prognostic factors and analyze differences in prognosis between younger and older patients stratified by tumor subtype. Methods: Of 10,950 breast cancer patients treated at West China Hospital between 1998 and 2017, 741 younger patients (P P P P = 0.024] and HR for DFS = 1.301 [95% CI, 1.077 - 1.572; P = 0.006]). When stratified by tumor subtype, younger patients with T1, N0, tumor stage I, G3, estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and Ki67 ≥ 14% had a poor BCSS; in addition, patients with T1, N1, tumor stages I and II, G3, ER-negative, PR-negative, and triple-negative had a poorer DFS than older patients. Conclusion: Young age was an independent prognostic factor for BCSS and DFS in breast cancer patients. The increased risk of relapse was most pronounced in early-stage breast cancer, especially in patients with ER-negative disease.
What problem does this paper attempt to address?